欧普康视2025年中报简析：净利润同比下降22.93%

Financial Performance - The company reported a net profit of 250 million yuan for the first half of 2025, a decrease of 22.93% year-on-year [1] - Total operating revenue for the same period was 871 million yuan, down 1.42% year-on-year [1] - The gross profit margin was 73.16%, a decrease of 0.83% compared to the previous year [1] - The net profit margin fell to 31.69%, down 21.65% year-on-year [1] - The total of selling, administrative, and financial expenses reached 311 million yuan, accounting for 35.72% of revenue, an increase of 20.76% year-on-year [1] Key Financial Metrics - Earnings per share (EPS) decreased to 0.28 yuan, down 23.20% year-on-year [1] - Operating cash flow per share was 0.35 yuan, a decrease of 3.63% year-on-year [1] - The company's net assets per share increased to 5.29 yuan, up 6.33% year-on-year [1] Changes in Financial Items - Cash and cash equivalents increased by 25.87% due to higher net income from investment activities [3] - Fixed assets increased by 57.56% as a result of the transfer of contact lens and related product industrialization construction projects [3] - Management expenses rose by 55.3% due to the reversal of stock option amortization expenses from the previous year [3] - Financial expenses surged by 203.81% due to decreased interest income from bank deposits [3] Investment Insights - The company's return on invested capital (ROIC) was 11.71%, indicating average capital returns [4] - Historical data shows a median ROIC of 24.99% since the company went public, suggesting strong investment returns over time [4] - The company's cash assets are reported to be very healthy, indicating good debt repayment capability [4] Fund Holdings - The largest fund holding the company’s shares is the Bodao Anyuan 6-Month Holding Period Mixed Fund, with a holding of 6,700 shares [5] - The fund's latest net value is 1.2742, reflecting a 0.21% increase from the previous trading day and an 11.22% increase over the past year [5]